Cargando…
Hypophosphatemia Due to Increased Effector Cell Metabolic Activity Is Associated with Neurotoxicity Symptoms in CD19-Targeted CAR T-cell Therapy
A major complication of chimeric antigen receptor (CAR) T-cell therapy is immune effector cell–associated neurotoxicity syndrome (ICANS), which presents as aphasia, confusion, weakness, somnolence, seizures, and coma. This is similar to the neurologic manifestations of hypophosphatemia, which can re...
Autores principales: | Tang, Jack Pengfei, Peters, Cole W., Quiros, Crystal, Wang, Xiaoyan, Klomhaus, Alexandra M., Yamada, Reiko E., Timmerman, John M., Moore, Theodore B., Nowicki, Theodore S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9722515/ https://www.ncbi.nlm.nih.gov/pubmed/36259217 http://dx.doi.org/10.1158/2326-6066.CIR-22-0418 |
Ejemplares similares
-
CRASH-IT Switch Enables Reversible and Dose-Dependent Control of TCR and CAR T-cell Function
por: Sahillioglu, Ali Can, et al.
Publicado: (2021) -
Characterization of Leukemic Resistance to CD19-Targeted CAR T-cell Therapy through Deep Genomic Sequencing
por: Chen, Gregory M., et al.
Publicado: (2023) -
Mechanisms of immune effector cell‐associated neurotoxicity syndrome after CAR‐T treatment
por: Gu, Tianning, et al.
Publicado: (2022) -
Amphetamine- and methamphetamine-induced hyperthermia: Implications of the effects produced in brain vasculature and peripheral organs to forebrain neurotoxicity
por: Bowyer, John F, et al.
Publicado: (2014) -
Cytokines in CAR T Cell–Associated Neurotoxicity
por: Gust, Juliane, et al.
Publicado: (2020)